Gut metabolites and colorectal cancer: associations leave prevention questions open
A review linked short-chain fatty acids with lower cancer odds, but mixed study designs and unclear exposure comparisons limit the conclusions.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
The review found associations between short-chain fatty acids and lower odds of colorectal cancer and advanced colorectal adenomas. It also described an intervention that increased butyrate in stool, a separate outcome. These findings do not establish that raising butyrate prevents cancer, or support dietary or probiotic recommendations for particular ancestry groups.
The abstract does not define the exposure contrast behind its odds ratios or report follow-up durations. It also does not show that intervention-related metabolite changes translate into fewer cancer cases.
What the abstract examined
The authors considered differences by ancestry and sample type; associations were not uniform. Because the review includes both observational studies and trials, results about cancer associations need to be distinguished from results about changing metabolite levels.
Separating biomarkers from cancer outcomes
The abstract reports a larger increase in stool butyrate with HAMSB than with traditional fiber. That comparison concerns metabolite levels; it does not demonstrate fewer cancer cases or establish a cancer-prevention benefit.
The original publication
Short-Chain Fatty Acids and Colorectal Cancer: A Systematic Review and Integrative Bayesian Meta-Analysis of Microbiome-Metabolome Interactions and Intervention Efficacy.
He Y, Peng K, Tan J et al.
Nutrients · 2025
- PubMed ID
- 41305603
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.